2
项与 Tarcidomgen Kimleucel 相关的临床试验Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)
Application of the Autologous CAR T Cells (Tarcidomgen Kimleucel) in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.
100 项与 Tarcidomgen Kimleucel 相关的临床结果
100 项与 Tarcidomgen Kimleucel 相关的转化医学
100 项与 Tarcidomgen Kimleucel 相关的专利(医药)
100 项与 Tarcidomgen Kimleucel 相关的药物交易